Curaxis Pharmaceutical (Curaxis Pharmaceutical) Change In Working Capital : $1.04 Mil (TTM As of Dec. 2011)

View and export this data going back to . Start your Free Trial

What is Curaxis Pharmaceutical Change In Working Capital?

Curaxis Pharmaceutical's change in working capital for the quarter that ended in Dec. 2011 was $1.04 Mil.

Curaxis Pharmaceutical's change in working capital for the fiscal year that ended in Dec. 2011 was $1.04 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Curaxis Pharmaceutical Change In Working Capital Historical Data

The historical data trend for Curaxis Pharmaceutical's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curaxis Pharmaceutical Change In Working Capital Chart

Curaxis Pharmaceutical Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Change In Working Capital

0.28

0.33

1.04

Curaxis Pharmaceutical Semi-Annual Data
	Dec08	Dec09	Dec10	Dec11
Change In Working Capital	-	0.28	0.33	1.04

Curaxis Pharmaceutical Change In Working Capital Calculation

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2011 was $1.04 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Curaxis Pharmaceutical Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Curaxis Pharmaceutical's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Curaxis Pharmaceutical (Curaxis Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Curaxis Pharmaceutical Corp (OTCPK:CURXQ) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.curaxispharma.com

Curaxis Pharmaceutical Corp was incorporated in Delaware on February 27, 2001. It is a specialty pharmaceutical company with a hormone drug product candidate for the treatment of Alzheimer's disease. The Company's therapeutic platform is based on the hypothesis that diseases of aging may be caused by age-related changes in the function of the hypothalamic-pituitary-gonadal (HPG) axis. The HPG axis is a hormonal endocrine feedback loop that controls development, reproduction and aging in animals. This drug development platform is built on the premise that hormones associated with this feedback loop are beneficial early in life, when they promote growth and development, but are harmful later in life when the mechanism for feedback is compromised, thereby leading to disease processes, including pathologies associated with Alzheimer's disease and various cancers. Its discovery of similar hormonal signaling mechanisms at the cellular level in brain tissue from Alzheimer's patients and in multiple tumors will enable it to develop significant new treatments for Alzheimer's disease and may have applications for many cancers.

Executives

Timothy R Wright	director, officer: Chief Executive Officer	C/O CURAXIS, 1004 CHAGFORD WAY, RALEIGH NC 27614
Michael W George	director	C/O CURAXIS, 1004 CHAGFORD WAY, RALEIGH NC 27614

Curaxis Pharmaceutical (Curaxis Pharmaceutical) Headlines

No Headlines